Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder

Inclusion Criteria: * Aged 18 to 65, male or female patient has a diagnosis of overactive bladder and the symptoms of OAB\>3 months subject has urinary frequency (average micturition frequency within 24h\>8 times), urgency and/or urge incontinence by micturition diary card during screening period * Mean volume of single micturition is less than 200ml by micturition diary dard during screening period * The subject is willing and able to complete the micturition diary card correctly * Subject's urine routine test show that he/she has no urinary tract infection Subject signs informed consent form Exclusion Criteria: * Confirmed by the investigator that subject has severe stress incontinence. * Subject who has serious heart disease or arrhythmia, in the investigator's opinion, is not suitable to enroll. * Subject who has contraindications of anticholinergic therapy, such as urinary retention, gastric retention and uncontrollable angle closure glaucoma. * Subject who has a symptomatic acute urinary tract infection. * Subject who has a recurrent urinary tract infection. * Subject who has interstitial cystitis. * Subject who has an agnogenic hematuria. * Subject who has a bladder outlet obstruction of clinical significance. * Subject who needs retention catheterization or intermittent catheterization. * Patient with malignant tumor. * Subject who has received anticholinergic drugs or other drugs for treating OAB within washout period, or who will receive these drugs after this study begins. * Subject who is pregnant or lactating, or plans to be pregnant subject who has received other clinical study drugs or its participating in other clinical trial within 30 days. * Women of childbearing age who has not taken sufficient contraception measures within 3 months before random number distribution; or intends to stop the contraception measures during the trial or within one month after the treatment is over.